Trials / Recruiting
RecruitingNCT06589778
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Safety, Tolerability, and Efficacy of SHR-A2102 in Combination With Adebrelimab, With SHR-8068, in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase IB/II Open-Label, Multicenter Clinical Study
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 124 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, open-label, dose-finding/efficacy-expanding Phase IB/II clinical trial to evaluate SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer. The study consists of two phases: Phase IB to explore the safety/tolerability of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer; Phase II: To explore the efficacy of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A2102 | SHR-A2102: injection, 80mg/ bottle, intravenous drip |
| DRUG | Adebelimab (SHR-1316) | Adebelimab (SHR-1316): injection, 600mg(12mL)/ bottle, intravenous drip |
| DRUG | SHR-8068 | SHR-8068: injection, 50mg（10mL）/ bottle, intravenous drip |
Timeline
- Start date
- 2024-09-27
- Primary completion
- 2026-04-30
- Completion
- 2026-04-30
- First posted
- 2024-09-19
- Last updated
- 2024-11-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06589778. Inclusion in this directory is not an endorsement.